Lung Cancer in the United Kingdom

Navani, Neal; Baldwin, David R; Edwards, John; Evison, Matthew; McDonald, Fiona; Nicholson, Andrew G.; Fenemore, Jackie; Sage, Elizabeth K.; Popat, Sanjay

doi:10.1016/j.jtho.2021.11.002

Cited by 9 publications

(12 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Systemic anticancer therapy requires regulatory and health technology appraisal for reimbursement. Private health insurance is uncommon [ 31 , 32 ].…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

How Can the EU Beating Cancer Plan Help in Tackling Lung Cancer, Colorectal Cancer, Breast Cancer and Melanoma?

et al. 2022

View full text Add to dashboard Cite

Cancer is the second leading cause of mortality in EU countries, and the needs to tackle cancer are obvious. New scientific understanding, techniques and methodologies are opening up horizons for significant improvements in diagnosis and care. However, take-up is uneven, research needs and potential outstrip currently available resources, manifestly beneficial practices—such as population-level screening for lung cancer—are still not generalised, and the quality of life of patients and survivors is only beginning to be given attention it merits. This paper, mainly based on a series of multistakeholder expert workshops organised by the European Alliance for Personalised Medicine (EAPM), looks at some of those specifics in the interest of planning a way forward. Part of this exercise also involves taking account of the specific nature of Europe and its constituent countries, where the complexities of planning a way forward are redoubled by the wide variations in national and regional approaches to cancer, local epidemiology and the wide disparities in health systems. Despite all the differences between cancers and national and regional resources and approaches to cancer care, there is a common objective in pursuing broader and more equal access to the best available care for all European citizens.

show abstract

“…Systemic anticancer therapy requires regulatory and health technology appraisal for reimbursement. Private health insurance is uncommon [ 31 , 32 ].…”

Section: Resultsmentioning

confidence: 99%

“…Surgery research is vital, and there are 61 well-equipped radiotherapy centres. Patient and physician advocacy is also strong, contributing to improved LC outcomes [ 31 ].…”

Section: Resultsmentioning

confidence: 99%

How Can the EU Beating Cancer Plan Help in Tackling Lung Cancer, Colorectal Cancer, Breast Cancer and Melanoma?

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Additionally, lung cancer treatments have further shifted towards more targeted regimens, after demonstrating better survival than existing therapy in trials [12]. Additionally, there has been a concurrent expansion of lung cancer surgery, which has been shown to further improve treatment outcomes [56], [57].…”

Section: Discussionmentioning

confidence: 99%

Incidence, prevalence, and survival of lung cancer in the United Kingdom from 2000-2021: a population-based cohort study

Corby,

Barclay,

Tan

et al. 2024

Preprint

View full text Add to dashboard Cite

BackgroundLung cancer is the leading cause of cancer-associated mortality worldwide. In the UK, there has been a major reduction in smoking, the leading risk factor for lung cancer, as well as the introduction of the new screening in 2023. Therefore, an up-to-date assessment of the trends of lung cancer is required in the UK.MethodsWe performed a population-based cohort study using the UK primary care Clinical Practice Research Datalink (CPRD) GOLD database, compared with CPRD Aurum. Participants aged 18+ years, with one-year of prior data availability, were included. We estimated lung cancer incidence rates (IR), period prevalence (PP), and survival at one-, five– and ten years after diagnosis using the Kaplan-Meier method.ResultsOverall, 11,388,117 participants, with 45,563 lung cancer cases were studied. The incidence rate of lung cancer was 52.0 (95% CI 51.5 to 52.5) per 100,000 person-years, with incidence increasing from 2000 to 2021, especially in females aged over 50, and males aged over 80, with the highest incidence rate in people aged 80-89. Period prevalence in 2021 was 0.18%, with the largest rise seen in participants aged over 60. Median survival post-diagnosis increased from 6.6 months in those diagnosed between 2000-2004 to 10 months between 2015-2019. Both short and long-term survival was higher in younger cohorts, with 82.7% one-year survival in those aged 18-29, versus 24.2% in the age 90+ cohort. Throughout the study period, survival was longer in females, with a larger increase in survival over time than in males.ConclusionThe incidence and prevalence of lung cancer diagnoses in the UK have increased, especially in female and older populations, with a small increase in median survival. With the introduction of the UK lung cancer screening programme, this study will enable future comparisons of overall disease burden, so the overall impact may be seen.

show abstract

“…Lung cancer exudes a profound impact in the UK, with national cancer registries noting an incidence of 47,838 cases diagnosed and 35,137 deaths recorded in 2018. 3 Prognosis is frequently poor, which is mainly associated with late presentation. 4 Therefore, early recognition is integral to more treatment options and better outcomes.…”

Section: Introductionmentioning

confidence: 99%

“…7 The past decade saw lung cancer age-standardised incidence rates increase by 1% overall, with a 15% increase and 11% decrease in the female and male population, respectively. 3 Although lung cancer age-standardised mortality rates decreased by 14% lung cancer continues to have the highest cancer-related mortality in the UK. In 2018, the 1-year survival was 83% for patients presenting with stage I disease but 17% for patients with stage IV disease.…”

Section: Introductionmentioning

confidence: 99%

Lung cancer recovery focus post pandemic: an income-deprived area paradigm

et al. 2023

View full text Add to dashboard Cite

Stage shift' has been proposed as a marker of impact of Coronavirus 2019 (COVID-19) in lung cancer services; however, there are no data available specifically from income-deprived areas. Thus, this study evaluated the impact of the COVID-19 pandemic on lung cancer care in our area (Corby; among the most income deprived in England) and identified focus recovery areas. The study was a retrospective observational study of 668 consecutive patients with lung cancer at a district general hospital, pre-, during and after the COVID peak. Outcomes were the overall number of cases, presenting staging and treatment pathway. Overall, 32 fewer patients were diagnosed during the pandemic, with more inpatient diagnoses (p=0.01) and fewer primary care referrals (p<0.0001). There were no differences observed in treatment intent or 'stage shift'. Our results suggest that COVID-19 negatively affected the whole lung cancer pathway in our area. However, 'stage shift' might not be ideal to assess the impact of COVID-19 in income-deprived areas. Further studies will help the strategic rollout of a screening programme to identify patients with lung cancer earlier on in such areas.

show abstract

Lung Cancer in the United Kingdom

Cited by 9 publications

References 6 publications

How Can the EU Beating Cancer Plan Help in Tackling Lung Cancer, Colorectal Cancer, Breast Cancer and Melanoma?

How Can the EU Beating Cancer Plan Help in Tackling Lung Cancer, Colorectal Cancer, Breast Cancer and Melanoma?

Incidence, prevalence, and survival of lung cancer in the United Kingdom from 2000-2021: a population-based cohort study

Lung cancer recovery focus post pandemic: an income-deprived area paradigm

Contact Info

Product

Resources

About